Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
A draft regulatory guide from the U.S. Nuclear Regulatory Commission could create major access barriers for Novartis' prostate cancer radioligand therapy Pluvicto. The proposed rules use overly conservative assumptions — including that caregivers never leave a patient's side — that would push a full Pluvicto treatment course over the allowable radiation release threshold. Experts warn smaller community clinics may simply stop offering the therapy altogether.
Novartis' Pluvicto, a radioligand therapy for prostate cancer, has been on a growth tear — but a proposed regulatory overhaul from the U.S. Nuclear Regulatory Commission (NRC) could throw a wrench in that momentum. The NRC's draft guide DG-8070 governs how patients are released after receiving radioactive treatments, and its updated math could make it nearly impossible to discharge Pluvicto patients as outpatients under standard protocols.
The core issue: the draft guide assumes a caregiver spends 100% of their time within 3 feet of a treated patient — an occupancy factor of 1, up from the current 0.25. Combined with a new rule that evaluates radiation exposure across an entire treatment course (rather than per dose), a full six-dose Pluvicto regimen would exceed the NRC's release threshold. That could force clinics to hold patients longer, hospitalize them unnecessarily, or perform complex individualized calculations — a tall order for community centers without dedicated nuclear medicine physicists.
By the Numbers:
Why it matters: The NRC's draft guide remains open for revision, and its own advisory committee has already flagged the occupancy factor as unrealistic. But if finalized as-is, the rules could deter community clinics from offering Pluvicto — precisely the sites driving its growth — creating a real-world access gap for prostate cancer patients who depend on this therapy.
